Key Metrics
CiteScore 

10.3
Eigenfactor 

0.005 - 0.01
H-Index 

97
Impact Factor 

5 - 10
SJR 

Q1Endocrinology

SNIP 

1.97
Recommended pre-submission checks
Powered by 

Topics Covered on Diabetes Technology and Therapeutics
Diabetes Technology and Therapeutics Journal Specifications
| Overview | |
| Publisher | MARY ANN LIEBERT, INC |
| Language | English |
| Frequency | Monthly |
| General Details | |
| Language | English |
| Frequency | Monthly |
| Publication Start Year | 1999 |
| Publisher URL | Visit website |
| Website URL | Visit website |
View less
Planning to publish in Diabetes Technology and Therapeutics ?
Upload your Manuscript to get
- Degree of match
- Common matching concepts
- Additional journal recommendations

Recently Published Papers in Diabetes Technology and Therapeutics
All-Cause Mortality and Health Care Resource Utilization in Patients with Type 1 Diabetes Treated with Glucagon-like Peptide 1 Receptor Agonists/Glucose-Dependent Insulinotropic Polypeptide.
- 22 Dec 2025
- Diabetes technology & therapeutics
Antigen-Specific Chimeric Antigen Receptor-T Regulatory Cells Home to Human Islets, Suppress Cytotoxic T Lymphocytes and Reverse Type 1 Diabetes.
- 22 Dec 2025
- Diabetes technology & therapeutics
Cost-Utility Analysis of Control-IQ Technology Relative to Conventional Insulin Therapy in Adults with Type 1 Diabetes.
- 22 Dec 2025
- Diabetes technology & therapeutics
Letter: Response to: "Lack of Association Between Hemoglobin A1c and Continuous Glucose Monitor Metrics Among Individuals with Prediabetes and Normoglycemia".
- 22 Dec 2025
- Diabetes technology & therapeutics
An Exploratory Analysis of Continuous Glucose Monitoring Metrics in Relation to Prediabetes in Youths with Obesity.
- 22 Dec 2025
- Diabetes technology & therapeutics
Twenty-Five Hours of Fasting with Automated Insulin Delivery in Youth with Type 1 Diabetes.
- 22 Dec 2025
- Diabetes technology & therapeutics
All-Cause Mortality and Health Care Resource Utilization in Patients with Type 1 Diabetes Treated with Glucagon-like Peptide 1 Receptor Agonists/Glucose-Dependent Insulinotropic Polypeptide.
- 22 Dec 2025
- Diabetes technology & therapeutics
Antigen-Specific Chimeric Antigen Receptor-T Regulatory Cells Home to Human Islets, Suppress Cytotoxic T Lymphocytes and Reverse Type 1 Diabetes.
- 22 Dec 2025
- Diabetes technology & therapeutics
Cost-Utility Analysis of Control-IQ Technology Relative to Conventional Insulin Therapy in Adults with Type 1 Diabetes.
- 22 Dec 2025
- Diabetes technology & therapeutics
Letter: Response to: "Lack of Association Between Hemoglobin A1c and Continuous Glucose Monitor Metrics Among Individuals with Prediabetes and Normoglycemia".
- 22 Dec 2025
- Diabetes technology & therapeutics
An Exploratory Analysis of Continuous Glucose Monitoring Metrics in Relation to Prediabetes in Youths with Obesity.
- 22 Dec 2025
- Diabetes technology & therapeutics
Twenty-Five Hours of Fasting with Automated Insulin Delivery in Youth with Type 1 Diabetes.
- 22 Dec 2025
- Diabetes technology & therapeutics
FAQs on Diabetes Technology and Therapeutics
How long has Diabetes Technology and Therapeutics been actively publishing? 
What is the publishing frequency of Diabetes Technology and Therapeutics? 
How many articles did Diabetes Technology and Therapeutics publish last year? 
What is the eISSN & pISSN for Diabetes Technology and Therapeutics? 
What is Citescore for Diabetes Technology and Therapeutics? 
What is the H Index for Diabetes Technology and Therapeutics ? 
What is SNIP score for Diabetes Technology and Therapeutics? 
What is the SJR for Diabetes Technology and Therapeutics? 
Who is the publisher of Diabetes Technology and Therapeutics? 
Check if your manuscript is a good match for
undefined
Upload your manuscript to get recommendations of journals
that have published papers similar to your manuscript
Drag and drop your file here
We accept manuscripts in English. File format: .doc and .docx | Maximum size: 10 MB | Word count: 200-300,000 words | File length: less than 100 pages
Do not have a manuscript right now? Use an abstract or summary